eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

vol. 10
Original paper

Importance of dynamic contrast enhanced magnetic resonance imaging for targeting biopsy and salvage treatments after prostate cancer recurrence

Josh Mason, Ese Adiotomre, Peter Bownes, Brendan Carey, Ann Henry

J Contemp Brachytherapy 2018; 10, 6: 570–572
Online publish date: 2018/11/17
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Evaluate T2 weighted MRI (T2W), diffusion weighted imaging (DWI), and dynamic contrast enhanced MRI (DCE-MRI) for determining areas of prostate cancer recurrence to target biopsy or salvage treatment in patients previously treated with I-125 seed brachytherapy.

Material and methods
MRI data from 15 patients, whose primary treatment was I-125 seed brachytherapy and who were subsequently treated with partial gland salvage high-dose-rate brachytherapy were retrospectively analyzed. Two radiologists independently reviewed imaging on two occasions blinded to clinical and biopsy information. At first review, the T2W and DWI sequences were assessed for likely presence of tumor and at second review, the additional DCE-MRI sequence was assessed. Results were recorded and compared on a prostate diagram divided into 12 sectors (quadrants at each of base, mid-gland, and apex) plus seminal vesicles (SV).

Number of patients for whom recurrence was visible was 7/15 for T2W, 6.5/15 for DWI, and 15/15 for DCE-MRI (average of results for the two radiologists). Approximately, half of the sectors identified as showing recurrence were at the anterior base of the prostate.

In prostate cancer patients previously treated with I-125 permanent seed implants, DCE-MRI is superior to T2W and DWI in defining areas of recurrence, and should be used to target biopsy and for treatment planning of focal salvage therapies.


cancer recurrence, multi-parametric MRI, prostate brachytherapy, targeted biopsy

Duijzentkunst DS, Peters M, van Zyp JvdV et al. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol 2016; 34: 1521-1531.
Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS prostate imaging–reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16-40.
Wu L, Xu J-R, Gu H et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol) 2013; 25: 252-264.
Roy C, Foudi F, Charton J et al. Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy. AJR Am J Roentgenol 2013; 200: W361-W368.
Haider MA, Chung P, Sweet J et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 425-430.
Rouvière O, Valette O, Grivolat S et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor – correlation with biopsy findings. Urology 2004; 63: 922-927.
Donati O, Jung S, Vargas H et al. Multiparametric Prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 2013; 268: 440-450.
Nasser NJ, Wang Y, Borg J, Saibishkumar EP. Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy. Brachytherapy 2014; 13: 369-374.
Mohamed Yoosuf AB, Workman G, O’Toole MM et al. Sector analysis of 125I permanent prostate brachytherapy provides a rapid and effective method of evaluating and comparing pre-and post-implant dosimetry. Brachytherapy 2013; 12: 254-259.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe